Company news
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) news
Bolt Biotherapeutics, Inc. news releases on 6ix. Latest, Aug 11, 2026: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides…
Press releases & updates
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 12, 2026
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
October 1, 2025
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
May 8, 2025
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
April 30, 2025
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
April 25, 2025
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
March 25, 2025
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 24, 2025
Bolt Biotherapeutics to Participate in Upcoming March Conferences
February 25, 2025
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
February 10, 2025
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
November 6, 2024
Bolt Biotherapeutics Announces Changes to its Board of Directors
September 3, 2024
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
May 13, 2024
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 20, 2024
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 4, 2023
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 22, 2023
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 17, 2023
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 16, 2023
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 15, 2023
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 27, 2023
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
September 11, 2023
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 6, 2023
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
August 2, 2023
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
May 24, 2023
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 25, 2023
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 28, 2023
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
March 28, 2023
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
March 13, 2023
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 13, 2022
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
November 6, 2022
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 11, 2022
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 29, 2022
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
January 5, 2022
Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
December 15, 2021
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
December 5, 2021
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
December 1, 2021
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 8, 2021
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
September 7, 2021
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
August 25, 2021
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 11, 2021